119.75
1.17%
-1.42
After Hours:
119.75
Zimmer Biomet Holdings Inc stock is currently priced at $119.75, with a 24-hour trading volume of 1.07M.
It has seen a -1.17% decreased in the last 24 hours and a -6.38% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $121.5 pivot point. If it approaches the $119.2 support level, significant changes may occur.
Previous Close:
$121.17
Open:
$120.71
24h Volume:
1.07M
Market Cap:
$24.60B
Revenue:
$7.39B
Net Income/Loss:
$1.02B
P/E Ratio:
49.69
EPS:
2.41
Net Cash Flow:
$1.20B
1W Performance:
+0.35%
1M Performance:
-6.38%
6M Performance:
+15.54%
1Y Performance:
-13.89%
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
574-267-6131
Address
345 East Main Street, Warsaw, IN
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-20-23 | Initiated | ROTH MKM | Neutral |
Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
Mar-29-23 | Initiated | UBS | Sell |
Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Oct-18-22 | Initiated | Barclays | Underweight |
Oct-12-22 | Initiated | Jefferies | Underperform |
May-27-22 | Downgrade | Needham | Buy → Hold |
Apr-13-22 | Downgrade | Truist | Buy → Hold |
Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
Mar-02-22 | Resumed | BofA Securities | Underperform |
Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Feb-08-22 | Reiterated | Citigroup | Buy |
Feb-08-22 | Reiterated | Deutsche Bank | Hold |
Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
Feb-08-22 | Reiterated | JP Morgan | Neutral |
Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
Feb-08-22 | Reiterated | Stifel | Buy |
Feb-08-22 | Reiterated | Truist | Buy |
Feb-08-22 | Reiterated | UBS | Neutral |
Feb-08-22 | Reiterated | Wells Fargo | Underweight |
Feb-02-22 | Downgrade | UBS | Buy → Neutral |
Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
Dec-07-21 | Initiated | Loop Capital | Buy |
Nov-23-21 | Downgrade | Argus | Buy → Hold |
Sep-14-21 | Resumed | Raymond James | Mkt Perform |
May-25-21 | Initiated | Barclays | Overweight |
Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-18-20 | Reiterated | Needham | Strong Buy |
Oct-20-20 | Initiated | Northland Capital | Market Perform |
Sep-11-20 | Initiated | Wolfe Research | Outperform |
Aug-05-20 | Reiterated | Needham | Strong Buy |
Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
Apr-07-20 | Reiterated | Needham | Strong Buy |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Buy |
Jan-08-20 | Initiated | SunTrust | Buy |
Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
Aug-12-19 | Upgrade | Argus | Hold → Buy |
Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Earnings Preview: Zimmer Biomet (ZBH) Q1 Earnings Expected to Decline
Zacks Investment Research
SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
Zacks Investment Research
What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?
Zacks Investment Research
Smith+Nephew (SNN) Expands in Australia With New Alliance
Zacks Investment Research
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Zacks Investment Research
Unveiling 7 Analyst Insights On Zimmer Biomet Holdings
Benzinga
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Zimmer Biomet Holdings Inc (ZBH) Revenue 2024
ZBH reported a revenue (TTM) of $7.39 billion for the quarter ending December 31, 2023, a +6.55% rise year-over-year.
Zimmer Biomet Holdings Inc (ZBH) Net Income 2024
ZBH net income (TTM) was $1.02 billion for the quarter ending December 31, 2023, a +342.52% increase year-over-year.
Zimmer Biomet Holdings Inc (ZBH) Cash Flow 2024
ZBH recorded a free cash flow (TTM) of $1.20 billion for the quarter ending December 31, 2023, a +9.78% increase year-over-year.
Zimmer Biomet Holdings Inc (ZBH) Earnings per Share 2024
ZBH earnings per share (TTM) was $4.89 for the quarter ending December 31, 2023, a +344.55% growth year-over-year.
Zimmer Biomet Holdings Inc Stock (ZBH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Winkler Lori | SVP and CHRO |
Apr 01 '24 |
Option Exercise |
0.00 |
772 |
0 |
3,551 |
Yi Sang | Group President, Asia Pacific |
Mar 07 '24 |
Option Exercise |
91.53 |
1,705 |
156,059 |
19,884 |
Yi Sang | Group President, Asia Pacific |
Mar 07 '24 |
Sale |
126.86 |
1,705 |
216,296 |
18,179 |
Upadhyay Suketu | Exec. VP, CFO |
Mar 06 '24 |
Option Exercise |
0.00 |
4,561 |
0 |
22,683 |
VAN ZUILEN WILFRED | Group Pres, EMEA |
Mar 06 '24 |
Option Exercise |
0.00 |
2,163 |
0 |
7,427 |
Winkler Lori | SVP and CHRO |
Mar 06 '24 |
Option Exercise |
0.00 |
1,757 |
0 |
3,207 |
Bezjak Mark | President, Americas |
Mar 06 '24 |
Option Exercise |
0.00 |
1,622 |
0 |
4,753 |
Ellingson Rachel | SVP & Chief Strategy Officer |
Mar 06 '24 |
Option Exercise |
0.00 |
1,419 |
0 |
7,291 |
Phipps Chad F | Sr. VP/Gen Counsel/Secretary |
Mar 06 '24 |
Option Exercise |
0.00 |
2,095 |
0 |
50,046 |
Stellato Paul A | VP, Controller & CAO |
Mar 06 '24 |
Option Exercise |
0.00 |
609 |
0 |
1,176 |
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Cap:
|
Volume (24h):